Showing results (21-30 of 49) with videos related to
Sort By:
Pageof 5
Oncotarget|October 2, 2015
First description of a sporadic breast cancer in a woman with BRCA1 germline mutationElsa Curtit, Vanessa Benhamo, Nadège Gruel, et al.Bulletin Du Cancer|October 17, 2019
[Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction]Julie Vardanega, Julie Henriques, Charlotte Pourcelot, et al.The Oncologist|June 1, 2013
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasisElsa Curtit, Virginie Nerich, Laura Mansi, et al.Bulletin Du Cancer|May 30, 2015
[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer]Marie-Justine Paillard, Elsa Curtit, Erion Dobi, et al.Breast (Edinburgh, Scotland)|January 12, 2019
Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practiceElsa Curtit, Jean-Michel Vannetzel, Jean-Claude Darmon, et al.BMC Cancer|December 31, 2013
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levelsStefano Kim, Erion Dobi, Marine Jary, et al.Journal of Neuro-Oncology|October 23, 2019
Complementary and alternative medicine use in glioma patients in FranceEmilie Le Rhun, Patrick Devos, Véronique Bourg, et al.Bulletin Du Cancer|August 6, 2014
[Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]Virginie Nerich, Elsa Curtit, Fernando Bazan, et al.Oncology Reports|February 11, 2017
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case reportGuillaume Meynard, Laura Mansi, Pierre Lebahar, et al.Frontiers in Cardiovascular Medicine|October 10, 2022
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumabQuentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, et al.Pageof 5